Skip to Content

Colgate-Palmolive looks like a bright and shiny weak-dollar play

Text SizeAAA

Filed under: Investing, Stock Picks

More

As the U.S. dollar continues to swoon anything denominated in greenbacks is getting a boost. Just witness what's happening in the commodity markets, where gold topped $1,100 an ounce Monday and oil is back flirting with 80 bucks a barrel.

That's made mining and energy stocks popular bets on the flaccid greenback -- but also kind of a crowded trade these days. For an alternative, longer-term wager on a weak dollar (and emerging-market growth), consumer products stalwart Colgate-Palmolive (CL) looks good.

Americans know Colgate for its eponymous toothpaste and dish soap, but about 80% of the world's biggest toothpaste maker's revenue comes from overseas. The weak dollar boosts Colgate's top-line results. Also appealing is that it derives so much of its foreign growth from fast-growing economies in Asia and Latin America.

Historically, Colgate has also been very kind to buy-and-hold investors. Over the past 25 years, those folks have enjoyed a total return of more than 5,200%. The S&P 500 ($INX), by comparison, returned a bit more than 1,125% over the same time.

True, Colgate's stock could be more favorable on a relative valuation basis, but by certain metrics, its attractive. By forward earnings, shares offer discounts of about 10% to the broader market and their own five-year average, according to Thomson Reuters. By price/earnings-to-growth (or PEG, which measures how fast a stock is rising relative to its growth prospects) the stock trades at about a 10% discount to the S&P.

Analysts' average price target stands at $86.13 a share. Add in the 2.2% dividend yield and you get an implied upside of more than 8% in the next 12 months or so. That's not too shabby for a well-run company poised to benefit from a weak dollar and some of the fastest growing economies in the world.

Add your comments

Please keep your comments relevant to this blog entry. Email addresses are never displayed, but they are required to confirm your comments.

When you enter your name and email address, you'll be sent a link to confirm your comment, and a password. To leave another comment, just use that password.

To create a live link, simply type the URL (including http://) or email address and we will make it a live link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br /> tags.

Interest Rates

5/1 ARM4.19%APR: 3.81%
30 Yr.
Fixed Mort.
5.02%APR: 5.16%
$30K
HELOC
8.00%APR: 0.00%
30 Mo
New Car Loan
6.79%APR: 0.00%
1 Yr. CD1.57%APR: 1.58%
DailyFinance Writers
Melly Alazraki Melly Alazraki Financial writer and analyst
James Altucher James Altucher Financial columnist
Jeff Bercovici Jeff Bercovici Media columnist
Jonathan Berr Jonathan Berr Financial writer and media columnist
Mercedes Cardona Mercedes Cardona Retail reporter
Tim Catts Tim Catts Financial writer
Peter Cohan Peter Cohan Author, venture capitalist and financial writer
Carrie Coolidge Carrie Coolidge Financial writer
Lita Epstein Lita Epstein Financial writer
Sam Gustin Sam Gustin Technology Writer
Nikhil Hutheesing Nikhil Hutheesing Tech and investing editor
Joseph Lazzaro Joseph Lazzaro Markets and economics writer
Latif Lewis Michelle Leder Financial Columnist
Latif Lewis Latif Lewis Business news editor and management columnist
Anthony Massucci Anthony Massucci Senior writer and tech columnist
Doug McIntyre Doug McIntyre Business and investing news writer and editor
Michael Mercurio Michael Mercurio Managing Editor
Todd Pruzan Todd Pruzan Features editor
Michael Rainey Michael Rainey Editor and economics writer
Alex Salkever Alex Salkever Senior technology writer
David Schepp David Schepp Business News reporter
Matthew Scott Matthew Scott Investing reporter and editor
Dan Solin Daniel R. Solin Author, investment advisor and retirement expert
Amey Stone Amey Stone Executive editor
Bruce Watson Mark Svenvold Columnist, renewable energy
Russel Turk, M.D. Russell Turk, M.D. Healthcare policy columnist
Bruce Watson Bruce Watson Features Writer
my portfolios

Find out why more people track their portfolios on AOL Money & Finance than anywhere else.

Create a New Portfolio My Portfolios

Daily Finance Partners

More from the Weblogs Network